Concepedia

Publication | Open Access

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

DOIFull Paper Access

375

Citations

25

References

2018

Year

Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William Proctor Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh,
British Journal of Cancer

Abstract

Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318).

References

YearCitations

Page 1